Delayed detection of subtle changes in neurological function can negatively affect patient outcomes. Patients and pharma would benefit from earlier detection of neurological decline, resulting in earlier diagnosis of neurological disorders and earlier therapeutic interventions. Our platform delivers a remote, quantitative assessment of neurological function with AI analysis. Our analysis incorporates data from our gamified mobile app and other digital biomarkers, such as our novel pulmonary device, providing HCPs and investigators a more sensitive, comprehensive neurological assessment earlier, faster, more reliably and conveniently than a standard clinical assessment. Our solution has demonstrated convergent validity with traditional neurological exams in studies at Yale and Weill-Cornell. Our app is already deployed to the general public with over 2500 MS users and is also being used in a Biogen post-marketing trial in MS. Expansion of our platform into early diagnosis and monitoring of Alzheimer’s disease, ALS, and Myasthenia Gravis is underway.
Larry Rubin, Chairman - email@example.com
Charisse Litchman, MD, Chief Medical Officer